Status and phase
Conditions
Treatments
About
Unresectable, non-metastatic cirrhosis-related hepatocellular carcinoma (HCC) has a poor prognosis as there are no recommended curative treatments. Chemoembolisation is the most widely used treatment in these patients, but this technique can prove to be toxic. intrahepatic arterial chemotherapy with lipiodol and idarubicin could be an effective therapeutic approach, without deteriorating liver function.
The rationale for this treatment can be resumed as follows:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically-proven hepatocellular carcinoma or carcinoma meeting validated non-invasive criteria (EASL, AASLD)
Exclusion criteria
Patients who can benefit from curative treatment (surgical resection, liver transplant or treatment via percutaneous destruction)
15 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal